Skip to main content

Table 1 Clinicopathological characteristics of patients

From: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance

Characteristic N (%)
Total 58 (100)
Pre-neoadjuvant TIL evaluation available 43 (74.1)
Post-neoadjuvant TIL evaluation available 58 (100)
Age (range 28–71 years)
 <50 years 28 (48.2)
 ≥50 years 30 (51.7)
Histotype
 Ductal 50 (86)
 Other 8 (3)
 DCIS foci 8 (13.7)
ER
 Negative 12 (20.6)
 Positive 45 (77.5)
 TNBC 9 (15.5)
PR
 Negative 17 (29.3)
 Positive 40 (68.9)
HER2
 Negative 46 (79.3)
 Positive 12 (20.6)
Lymph node status
 Negative 21 (36.2)
 Positive 37 (63.7)
Residual tumor size
 <2 cm 24 (41.3)
  > 2 cm 34 (58.6)
Grade at diagnosis
 1 and 2 37 (63.7)
 3 19 (32.75)
 N/A 2 (0.034)
Relapse
 No relapse 25 (43.1)
 Relapse 11 (18.9)
 N/A 22 (37.9)
Neoadjuvant chemotherapy
 AC/taxane 33 (56.8)
 Other 25 (43.1)
  1. TIL tumor infiltrating lymphocyte, DCIS ductal carcinoma in situ, ER estrogen receptor, TNBC triple-negative breast cancer, PR progesterone receptor, HER human epidermal growth factor, AC anthracycline, N/A not available